BEAT — HeartBeam, Inc.

HeartBeam (BEAT) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $5.3 million, or $0.15 per share, consistent with the previous quarter and in line with expectations.
• Cash Used in Operating Activities: $3.2 million, an 8% decrease quarter-over-quarter, building on a 23% decrease from the prior quarter.
• Cash and Cash Equivalents: $1.9 million as of September 30, 2025. The company is closely monitoring its cash position and is focused on minimizing shareholder dilution.

2. Strategic Updates and Business Highlights

• Product Development: HeartBeam is advancing its portable, cable-free ECG technology, which synthesizes a 12-Lead ECG. The company received FDA 510(k) clearance for arrhythmia assessment in December 2024 and is awaiting clearance for its 12-Lead ECG synthesis software by year-end 2025.
• Partnerships: A significant agreement was established with HeartNexus, a network of U.S.-based cardiologists, to provide on-demand ECG interpretations.
• Ecosystem Development: HeartBeam is building a comprehensive ecosystem around its product, including automated assessments, integration with wearables, and educational content to enhance user engagement.
• Intellectual Property: The company now holds 24 issued patents and was recognized as a leader in portable cardiac diagnostics.

3. Forward Guidance and Outlook

• Commercial Launch: Anticipated for early 2026 following FDA clearance. Initial focus will be on prominent concierge and preventive cardiology practices in Southern California and South Florida.
• Sales Strategy: The company plans to adopt a subscription model, offering the device and a certain number of cardiology reads as part of the initial package.
• Growth Expectations: While early revenue projections are modest, significant growth is expected in the second half of 2026 as the company expands its market reach.

4. Bad News, Challenges, or Points of Concern

• Cash Position: With only $1.9 million in cash, there are concerns about the company's ability to fund operations until commercialization begins. The management is exploring funding options to strengthen the balance sheet.
• Regulatory Risks: The company is navigating the FDA clearance process, which carries inherent uncertainties that could impact timelines and commercialization plans.
• Market Competition: HeartBeam is entering a competitive landscape with existing ECG solutions, necessitating a clear differentiation strategy to capture market share.

5. Notable Q&A Insights

• FDA Discussions: Management described ongoing discussions with the FDA as productive but did not disclose specific details regarding the nature of the inquiries.
• Market Launch Strategy: The initial launch will focus on a few key territories to gather feedback and refine the business model before broader expansion.
• Pricing Strategy: The company is considering a subscription model with different pricing tiers for symptomatic versus asymptomatic readings, although specifics are still under development.
• Manufacturing Capabilities: HeartBeam expressed confidence in its manufacturing partner and the ability to produce devices using off-the-shelf components, minimizing supply chain concerns.
• Future Indications: Plans to pursue additional indications for myocardial infarction detection are in discussion with the FDA, indicating a pathway for future product expansion.

This summary encapsulates the key points from HeartBeam's Q3 2025 earnings call, highlighting both the company's progress and the challenges it faces as it prepares for commercialization.